{
  "schemaVersion": 2,
  "eyebrow": "Critical Care",
  "title": "Neurogenic Shock",
  "summary": "Neurogenic shock is acute distributive shock after high spinal cord injury, driven by loss of sympathetic tone and often accompanied by bradycardia. Immediate priorities are trauma resuscitation, exclusion of hemorrhage and other shock states, invasive hemodynamic monitoring, and blood-pressure augmentation while definitive spinal evaluation proceeds.",
  "seoDescription": "Physician review of neurogenic shock after spinal cord injury, including recognition, exclusion of hemorrhage, hemodynamic support, vasopressors, and monitoring.",
  "clinicalQuestion": "How should clinicians recognize and stabilize neurogenic shock after acute spinal cord injury?",
  "specialty": "Critical Care Medicine",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "neurogenic shock",
    "spinal cord injury",
    "hypotension",
    "bradycardia",
    "vasopressors",
    "mean arterial pressure"
  ],
  "keyTakeaways": [
    "Acute spinal pathology above T6 can interrupt sympathetic outflow below the lesion, producing hypotension from loss of vascular tone; reduced heart rate, cardiac output, and systemic vascular resistance may coexist. [21][23]",
    "In an injured patient, neurogenic shock is a diagnosis made alongside—not instead of—active evaluation and treatment for hemorrhagic and other causes of shock.",
    "Critical-care management described in neurosurgical literature includes MAP augmentation above 85 mm Hg for 3 to 7 days after acute spinal cord injury; the supporting source characterizes dopamine or norepinephrine as options and cautions that phenylephrine may cause reflex bradycardia. [23]",
    "Angiotensin II is FDA-labeled to raise blood pressure in adults with septic or other distributive shock; its recommended starting dose is 20 ng/kg/min by continuous IV infusion. Its role specifically in neurogenic shock is not established by the supplied evidence. [1][6]"
  ],
  "sections": [
    {
      "id": "recognition-and-physiology",
      "eyebrow": "Clinical phenotype",
      "heading": "Recognize the hemodynamic syndrome and localize the lesion",
      "intro": "Treat shock immediately while defining its mechanism.",
      "paragraphs": [
        "Neurogenic shock follows acute disruption of sympathetic pathways, classically from spinal cord pathology above T6. The resulting loss of sympathetic tone below the lesion lowers vascular tone and can produce hypotension. In acute spinal cord injury, disconnected sympathetic innervation is associated with decreased heart rate, blood pressure, cardiac output, and systemic vascular resistance. [21][23]",
        "The bedside pattern of hypotension with inappropriately low or reduced heart rate after cervical or high thoracic spinal cord injury should raise suspicion, but it should not close the diagnostic evaluation. Trauma-associated hypotension requires parallel assessment for bleeding, mechanical obstruction, myocardial dysfunction, drug effects, and sepsis when clinically plausible."
      ],
      "bullets": [
        "Suspect neurogenic shock in acute cervical or thoracic spinal cord injury with hypotension and bradycardia or absent compensatory tachycardia. [21][23]",
        "Use the neurologic examination and spinal imaging pathway to identify injury level and structural compression requiring specialty management.",
        "Differentiate neurogenic shock from spinal shock: spinal shock describes transient areflexia or hyporeflexia after spinal cord injury, whereas neurogenic shock denotes hemodynamic failure from sympathetic disruption. [23]"
      ],
      "subsections": [],
      "table": {
        "caption": "Hemodynamic implications of acute spinal cord injury [21][23]",
        "columns": [
          "Finding",
          "Clinical implication"
        ],
        "rows": [
          [
            "Injury above T6",
            "Loss of sympathetic tone below the lesion can cause hypotension. [21]"
          ],
          [
            "Bradycardia or low-normal heart rate during hypotension",
            "Supports impaired sympathetic cardiac response; assess for other contributors and treat unstable bradycardia according to the clinical context. [23]"
          ],
          [
            "Low cardiac output and systemic vascular resistance",
            "Supports a distributive hemodynamic phenotype and need for monitored resuscitation and vasopressor-based support when hypotension persists. [23]"
          ]
        ]
      }
    },
    {
      "id": "initial-stabilization",
      "eyebrow": "First hours",
      "heading": "Stabilize in a monitored critical-care setting",
      "intro": "Prevent secondary spinal cord ischemia while maintaining trauma priorities.",
      "paragraphs": [
        "Patients with suspected neurogenic shock after acute spinal cord injury require close hemodynamic monitoring in an ICU-level setting. A neurosurgical review describes arterial-line consideration and ICU admission to ensure blood-pressure stability during the immediate period after injury. [23]",
        "Initial care should proceed as trauma resuscitation: secure oxygenation and ventilation, protect the spine, establish reliable vascular access, identify and control hemorrhage, and reassess perfusion after each intervention. Do not attribute refractory hypotension solely to neurogenic shock until hemorrhage and other immediately reversible causes have been actively considered.",
        "Fluid administration may be necessary when hypovolemia is present, but persistent vasodilatory hypotension should prompt vasopressor support rather than repeated unbounded fluid loading. This distinction is especially important when reduced cardiac output, pulmonary complications, or concomitant injury limits fluid tolerance."
      ],
      "bullets": [
        "Continuous ECG, frequent blood-pressure measurement, serial neurologic examinations, urine output, and repeated assessment of peripheral perfusion are appropriate during active shock management.",
        "Consider an arterial catheter when continuous blood-pressure targeting or frequent blood sampling is needed; this is specifically noted as potentially warranted in acute spinal cord injury care. [23]",
        "Involve spine surgery or neurosurgery early for unstable injury, cord compression, or a lesion requiring decompression or fixation."
      ],
      "subsections": [],
      "table": {
        "caption": "Early bedside priorities in suspected neurogenic shock",
        "columns": [
          "Priority",
          "Action",
          "Reason"
        ],
        "rows": [
          [
            "Spinal protection",
            "Maintain immobilization appropriate to the suspected level of injury and obtain urgent spinal evaluation.",
            "Further displacement or unrecognized compression may worsen neurologic injury."
          ],
          [
            "Competing shock causes",
            "Conduct repeated trauma-focused evaluation for hemorrhage and evaluate other shock mechanisms as indicated.",
            "Neurogenic shock can coexist with hemorrhage or cardiopulmonary injury."
          ],
          [
            "Hemodynamic surveillance",
            "Use ICU-level monitoring; consider an arterial line when needed for MAP-directed management. [23]",
            "Rapid recognition of hypotension and bradycardia supports timely escalation."
          ]
        ]
      }
    },
    {
      "id": "blood-pressure-targets",
      "eyebrow": "Hemodynamic strategy",
      "heading": "Use MAP augmentation selectively and document the evidence limits",
      "intro": "Targeting is intended to support cord perfusion during the acute injury phase.",
      "paragraphs": [
        "A neurosurgical review describes medical management of acute spinal cord injury with MAP augmentation above 85 mm Hg for 3 to 7 days. [23] This target should be individualized to the injury pattern, concurrent bleeding, cardiac function, arrhythmia risk, and the ability to provide invasive monitoring. The supplied search results do not provide a current formal U.S. guideline recommendation, comparative vasopressor trial data, or an evidence-based lower or upper duration threshold.",
        "Avoid interpreting a MAP goal as a substitute for source control of bleeding, decompression when indicated, respiratory support, or definitive stabilization of the spinal injury. Reassess the need for pressors continuously as vasoplegia and bradycardia evolve."
      ],
      "bullets": [
        "Document baseline and achieved MAP, vasopressor dose, heart-rate trend, perfusion markers, and complications during MAP augmentation.",
        "Escalate evaluation if hypotension remains disproportionate to the neurologic lesion or is accompanied by evidence of blood loss, hypoxemia, chest injury, ischemic ECG changes, or new ventricular dysfunction.",
        "The supplied sources support a commonly used MAP strategy but do not establish an optimal vasopressor, exact titration protocol, or outcome benefit for every acute spinal cord injury phenotype."
      ],
      "subsections": [],
      "table": {
        "caption": "Blood-pressure support statements available from supplied sources",
        "columns": [
          "Intervention",
          "Available support",
          "Practical limitation"
        ],
        "rows": [
          [
            "MAP augmentation",
            "MAP greater than 85 mm Hg for 3 to 7 days is described in a neurosurgical review of acute spinal cord injury management. [23]",
            "The supplied evidence does not provide a contemporary guideline grade, individualized target framework, or comparative efficacy data."
          ],
          [
            "Norepinephrine or dopamine",
            "The review identifies dopamine or norepinephrine for MAP augmentation in this setting. [23]",
            "No dosing, comparative outcomes, or selection algorithm is provided in the supplied result."
          ],
          [
            "Phenylephrine",
            "The review advises dopamine or norepinephrine rather than phenylephrine because phenylephrine can cause reflex bradycardia in neurogenic shock. [23]",
            "This is source-specific expert guidance; individual use requires hemodynamic and rhythm assessment."
          ]
        ]
      }
    },
    {
      "id": "vasopressor-selection",
      "eyebrow": "Pharmacology",
      "heading": "Select vasoactive therapy by vasoplegia, chronotropy, and safety",
      "intro": "Evidence supplied here supports principles more clearly than a definitive drug hierarchy.",
      "paragraphs": [
        "For acute spinal cord injury with neurogenic shock, dopamine or norepinephrine are described as agents for MAP augmentation, with a specific caution that phenylephrine can precipitate reflex bradycardia. [23] In practice, selection should account for the degree of bradycardia, ventricular function, arrhythmia susceptibility, and the need for predominantly vasoconstrictor versus combined inotropic and chronotropic effects.",
        "Angiotensin II is FDA-labeled as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. The DailyMed label recommends a starting dose of 20 ng/kg/min by continuous IV infusion. [1][6] Neurogenic shock is a distributive state, but the supplied sources do not establish efficacy, safety, or a preferred place for angiotensin II in this specific condition; using it for neurogenic shock should therefore be considered off-label."
      ],
      "bullets": [
        "Norepinephrine: described as an option for MAP augmentation after acute spinal cord injury. [23]",
        "Dopamine: described as an option for MAP augmentation after acute spinal cord injury. [23]",
        "Phenylephrine: use requires caution in neurogenic shock because reflex bradycardia is a reported concern in the supplied neurosurgical review. [23]",
        "Angiotensin II: FDA-labeled for septic or other distributive shock at a recommended initial continuous IV infusion of 20 ng/kg/min; neurogenic-shock use is not supported by the supplied evidence and is off-label. [1][6]"
      ],
      "subsections": [],
      "table": {
        "caption": "Vasoactive agents referenced in supplied sources",
        "columns": [
          "Agent",
          "Source-supported role",
          "Key selection issue"
        ],
        "rows": [
          [
            "Norepinephrine",
            "Option for MAP augmentation in acute spinal cord injury. [23]",
            "Supplied sources do not provide dose or comparative outcomes."
          ],
          [
            "Dopamine",
            "Option for MAP augmentation in acute spinal cord injury. [23]",
            "Supplied sources do not provide dose or comparative outcomes."
          ],
          [
            "Phenylephrine",
            "Not favored over dopamine or norepinephrine in the cited review. [23]",
            "May cause reflex bradycardia in neurogenic shock. [23]"
          ],
          [
            "Angiotensin II",
            "FDA-labeled vasoconstrictor for adults with septic or other distributive shock; start 20 ng/kg/min by continuous IV infusion. [1][6]",
            "Specific neurogenic-shock evidence is absent in the supplied results; use would be off-label."
          ]
        ]
      }
    },
    {
      "id": "definitive-spinal-care",
      "eyebrow": "Concurrent management",
      "heading": "Pair hemodynamic rescue with injury-directed care and complication prevention",
      "intro": "Shock management cannot be separated from definitive spinal cord injury care.",
      "paragraphs": [
        "After physiologic stabilization, urgent characterization of cord compression, instability, and associated injuries directs operative and nonoperative management. The supplied sources note early decompression for cauda equina compression and emphasize critical-care admission after acute spinal injury to maintain blood-pressure stability. [23] They do not provide sufficient evidence to specify decompression timing or operative indications for every spinal injury pattern.",
        "The same review describes supportive elements of acute spinal cord injury care, including lower-extremity compression, abdominal binder use to improve MAP, cough assistance, nutritional support, ulcer prophylaxis, rehabilitation consultation, and early mobilization. [23] Apply these measures according to injury pattern, contraindications, respiratory status, and institutional protocols."
      ],
      "bullets": [
        "Assess and manage respiratory compromise aggressively, particularly with cervical injury.",
        "Initiate early multidisciplinary planning involving critical care, spine surgery or neurosurgery, trauma, rehabilitation, nursing, and respiratory therapy.",
        "Monitor for complications of immobilization and spinal cord injury, including venous thromboembolism, pulmonary complications, ileus, pressure injury, and urinary dysfunction; the supplied review identifies preventive supportive strategies but does not provide regimen-level details. [23]"
      ],
      "subsections": [],
      "table": {
        "caption": "Supportive measures described for acute spinal cord injury [23]",
        "columns": [
          "Measure",
          "Intended purpose"
        ],
        "rows": [
          [
            "Lower-extremity compression stockings",
            "Reduce risk of deep vein thrombosis and pulmonary embolism. [23]"
          ],
          [
            "Abdominal binder",
            "Improve MAP. [23]"
          ],
          [
            "Cough assistance",
            "Reduce risk of pneumonia. [23]"
          ],
          [
            "Early mobilization and rehabilitation consultation",
            "Support recovery and reduce complications of immobility. [23]"
          ]
        ]
      }
    }
  ],
  "faq": [
    {
      "question": "What finding most strongly suggests neurogenic rather than hemorrhagic shock after spinal trauma?",
      "answer": "Hypotension with bradycardia or an inappropriately absent tachycardic response after cervical or high thoracic cord injury supports neurogenic shock, reflecting loss of sympathetic tone. However, bleeding must still be actively excluded because shock mechanisms may coexist. [21][23]"
    },
    {
      "question": "What MAP target is used in acute spinal cord injury with neurogenic shock?",
      "answer": "A neurosurgical review describes augmenting MAP above 85 mm Hg for 3 to 7 days in acute spinal cord injury. [23] The supplied search results do not establish a universally optimal target, duration, or patient-specific escalation threshold."
    },
    {
      "question": "Which vasopressor is preferred in neurogenic shock?",
      "answer": "The supplied review identifies norepinephrine or dopamine for MAP augmentation and advises them over phenylephrine because phenylephrine may cause reflex bradycardia. [23] It does not provide comparative trial evidence or dosing to establish a universal first-line agent."
    },
    {
      "question": "Is angiotensin II indicated for neurogenic shock?",
      "answer": "Angiotensin II is FDA-labeled for adults with septic or other distributive shock, with a recommended initial continuous infusion of 20 ng/kg/min. [1][6] The supplied sources do not establish its role in neurogenic shock; use for that indication is off-label."
    }
  ],
  "references": [
    {
      "number": 1,
      "title": "Label: GIAPREZA- angiotensin ii injection - DailyMed",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c265d69a-3efe-4107-9a9e-e6fd3d531c48",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov"
    },
    {
      "number": 2,
      "title": "Maxipime for Injection - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/050679Orig1s000rev.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov"
    },
    {
      "number": 3,
      "title": "214787Orig1s010 - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214787Orig1s010.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov"
    },
    {
      "number": 4,
      "title": "FDA Adverse Event Reporting System Freedom of Information ...",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/FAERS%20Detailed%20HCQ%20100120%206953.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov"
    },
    {
      "number": 5,
      "title": "2021 First Generic Drug Approvals | FDA",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2021-first-generic-drug-approvals",
      "authors": "www.fda.gov",
      "host": "www.fda.gov"
    },
    {
      "number": 6,
      "title": "Label: ANGIOTENSIN II injection - DailyMed",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=727d1102-fc46-46f8-b78e-fd13f0738fe4&audience=consumer",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov"
    },
    {
      "number": 7,
      "title": "022569Orig1s000 - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022569Orig1s000MedR.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov"
    },
    {
      "number": 8,
      "title": "PRAMIPEXOLE DIHYDROCHLORIDE                                           0.125 mg, 0.25 mg, 0.5 mg, 1 mg, and 1.5 mg Tablets",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=04bf2b80-5371-4641-bbf5-e19587c0e9cf",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov"
    },
    {
      "number": 9,
      "title": "CLINICAL REVIEW",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/media/130098/download",
      "authors": "www.fda.gov",
      "host": "www.fda.gov"
    },
    {
      "number": 10,
      "title": "Subject:",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/media/192256/download",
      "authors": "www.fda.gov",
      "host": "www.fda.gov"
    },
    {
      "number": 11,
      "title": "Efficacy and safety of phospholipid nanoparticles (VBI-S) in ...",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00009-9/fulltext",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com"
    },
    {
      "number": 12,
      "title": "2017 ACC/AHA/HRS Guideline for the Evaluation and ...",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jacc.2017.03.003",
      "authors": "www.jacc.org",
      "host": "www.jacc.org"
    },
    {
      "number": 13,
      "title": "Stress Cardiomyopathy Diagnosis and Treatment: JACC State-of-the-Art Review",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jacc.2018.07.072",
      "authors": "www.jacc.org",
      "host": "www.jacc.org"
    },
    {
      "number": 14,
      "title": "2023 Guideline for the Management of Patients With ...",
      "detail": "www.ahajournals.org",
      "url": "https://www.ahajournals.org/doi/10.1161/STR.0000000000000436",
      "authors": "www.ahajournals.org",
      "host": "www.ahajournals.org"
    },
    {
      "number": 15,
      "title": "2023 ACC Expert Consensus Decision Pathway on ...",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jacc.2022.11.022",
      "authors": "www.jacc.org",
      "host": "www.jacc.org"
    },
    {
      "number": 16,
      "title": "Current Concepts on the Management of Shock | Circulation",
      "detail": "www.ahajournals.org",
      "url": "https://www.ahajournals.org/doi/10.1161/01.CIR.16.6.1097",
      "authors": "www.ahajournals.org",
      "host": "www.ahajournals.org"
    },
    {
      "number": 17,
      "title": "A prospective evaluation of hemodynamic management in ...",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/sc201332",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 18,
      "title": "Modeling trajectories of routine blood tests as dynamic biomarkers for outcome in spinal cord injury",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41746-025-01782-0",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 19,
      "title": "Hyponatremia in spinal cord injury patients: new insight ...",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/sc2014240",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 20,
      "title": "Spinal cord injury: molecular mechanisms and therapeutic interventions | Signal Transduction and Targeted Therapy",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41392-023-01477-6",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 21,
      "title": "Spinal Cord Anatomy and Localization | Continuum",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2021/02000/spinal_cord_anatomy_and_localization.4.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 22,
      "title": "Key Points for Issue | Continuum",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2024/02000/key_points_for_issue.21.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 23,
      "title": "Spine : Operative Neurosurgery",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/onsonline/fulltext/10.1093/ons/opz073~spine",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 24,
      "title": "Urogenital Symptoms in Neurologic Patients",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2017/04000/urogenital_symptoms_in_neurologic_patients.14.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "Label: GIAPREZA- angiotensin ii injection - DailyMed",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c265d69a-3efe-4107-9a9e-e6fd3d531c48",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov",
      "snippet": "The recommended starting dosage of GIAPREZA is 20 nanograms (ng)/kg/min via continuous intravenous infusion. of distributive shock such as neurogenic shock.",
      "score": 0.41933936
    },
    {
      "number": 2,
      "title": "Maxipime for Injection - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/050679Orig1s000rev.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov",
      "snippet": "criteria =ontnon to all other UTI protocols submitted in this application were employed in study #071. Exceptions are noted below. Study #07l specifically sought to enroll patien~s with uncomplicated OTI. Patients with impaired renal or hepatic function were excluded. Patients with a history of neur",
      "score": 0.294469
    },
    {
      "number": 3,
      "title": "214787Orig1s010 - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214787Orig1s010.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov",
      "snippet": "syndrome (ARDS) (requiring intubation), cardiogenic shock (requiring vasopressors), acute renal failure (requiring dialysis), who developed hepatic failure in the setting of multi-organ failure. Narrative noted that some level of organ dysfunction had occurred prior to RDV dosing. • Case 2020-046613",
      "score": 0.2774025
    },
    {
      "number": 4,
      "title": "FDA Adverse Event Reporting System Freedom of Information ...",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/FAERS%20Detailed%20HCQ%20100120%206953.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov",
      "snippet": "OTC Role Route Dosage Text Duration Mfr Off Label Use; Shock Haemorrhagic Hydroxychloroquine Sulfate (Authorized Generic),Plaquenil S Oral 400 Mg, Qd, Daily Concordia FDA Received Date Case # Case Type Health Prof Outcomes Mfr Control # 503B Facility Age Sex Country 26-Jun-2020 17946101 NON-EXPEDITE",
      "score": 0.24600808
    },
    {
      "number": 5,
      "title": "2021 First Generic Drug Approvals | FDA",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2021-first-generic-drug-approvals",
      "authors": "www.fda.gov",
      "host": "www.fda.gov",
      "snippet": "| 18 | 214017 | Droxidopa Capsules, 100 mg, 200 mg, 300 mg | ScieGen Pharmaceuticals, Inc. | Northera (Droxidopa) Capsules, 100 mg, 200 mg, 300 mg | 2/18/2021 | For the treatment of orthostatic dizziness or lightheadedness in adult patients with symptomatic neurogenic orthostatic hypotension |\n| 17 ",
      "score": 0.2416598
    },
    {
      "number": 6,
      "title": "Label: ANGIOTENSIN II injection - DailyMed",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=727d1102-fc46-46f8-b78e-fd13f0738fe4&audience=consumer",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov",
      "snippet": "Angiotensin II Injection is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. neurogenic shock.",
      "score": 0.22738393
    },
    {
      "number": 7,
      "title": "022569Orig1s000 - accessdata.fda.gov",
      "detail": "www.accessdata.fda.gov",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022569Orig1s000MedR.pdf",
      "authors": "www.accessdata.fda.gov",
      "host": "www.accessdata.fda.gov",
      "snippet": "dose adjustment was problematic. In conjunction with the safety findings (see Section 8), we found no evidence that the coarse increments for dose adjustment were problematic. If intolerable side effects were encountered or the patient did not experience adequate analgesia at 800 mcg, the patient wa",
      "score": 0.22235417
    },
    {
      "number": 8,
      "title": "PRAMIPEXOLE DIHYDROCHLORIDE                                           0.125 mg, 0.25 mg, 0.5 mg, 1 mg, and 1.5 mg Tablets",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=04bf2b80-5371-4641-bbf5-e19587c0e9cf",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov",
      "snippet": "#### Psychiatric disorders\n\naffect lability, aggression, agitation, bradyphrenia, bruxism, suicide, delirium, delusional disorder persecutory type, disorientation, dissociation, emotional distress, euphoric mood, hallucination auditory, hallucination visual, initial insomnia, libido increased, mania",
      "score": 0.18674712
    },
    {
      "number": 9,
      "title": "CLINICAL REVIEW",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/media/130098/download",
      "authors": "www.fda.gov",
      "host": "www.fda.gov",
      "snippet": "dose range for adult patients with POS is 150 to 600 mg/day, which approximates 2.5-10 mg/kg/day for an average 60 kg adult patient. The recommended dose range for pediatric patients with POS age 4 to 16 years of age and weighing ≥ 30 kg is 2.5-10 mg/kg/day (maximum 600 mg/day) and the recommended d",
      "score": 0.18042447
    },
    {
      "number": 10,
      "title": "Subject:",
      "detail": "www.fda.gov",
      "url": "https://www.fda.gov/media/192256/download",
      "authors": "www.fda.gov",
      "host": "www.fda.gov",
      "snippet": "Imported Product weight ≥ 27 kg: 1,200,000 units in a single dose. Prevention of diphtheria (including elimination of the asymptomatic carrier state): - children aged < 6 years (or weight < 30 kg): 600,000 units in a single dose - children aged ≥ 6 years (or weight ≥ 30 kg): 1,200,000 units in a sin",
      "score": 0.1632989
    },
    {
      "number": 11,
      "title": "Efficacy and safety of phospholipid nanoparticles (VBI-S) in ...",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00009-9/fulltext",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com",
      "snippet": "by C Simpkins · 2024 · Cited by 8 — Neurogenic shock due to. We also observed improvement in renal function as a reduction in creatinine at 48 h. improvements in the",
      "score": 0.17154673
    },
    {
      "number": 12,
      "title": "2017 ACC/AHA/HRS Guideline for the Evaluation and ...",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jacc.2017.03.003",
      "authors": "www.jacc.org",
      "host": "www.jacc.org",
      "snippet": "| See Online Data Supplement 16. | The care of patients with neurogenic OH is complex, especially in individuals with neurodegenerative disease. Care providers must be knowledgeable in the pathophysiology of the autonomic nervous system and the pharmacology of treatments for neurodegenerative diseas",
      "score": 0.5236402
    },
    {
      "number": 13,
      "title": "Stress Cardiomyopathy Diagnosis and Treatment: JACC State-of-the-Art Review",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jacc.2018.07.072",
      "authors": "www.jacc.org",
      "host": "www.jacc.org",
      "snippet": "Crossref\n\nPubMed\n\nGoogle Scholar\n\n20.\n\nBiso S., Wongrakpanich S., Agrawal A., Yadlapati S., Kishlyansky M. and Figueredo V.: A review of neurogenic stunned myocardium. _Cardiovasc Psychiatry Neurol_ 2017; 2017: 5842182.\n\nCrossref\n\nPubMed\n\nGoogle Scholar\n\n21.\n\nDel Buono M., Carbone S. and Abbate A.: ",
      "score": 0.13171978
    },
    {
      "number": 14,
      "title": "2023 Guideline for the Management of Patients With ...",
      "detail": "www.ahajournals.org",
      "url": "https://www.ahajournals.org/doi/10.1161/STR.0000000000000436",
      "authors": "www.ahajournals.org",
      "host": "www.ahajournals.org",
      "snippet": "by BL Hoh · 2023 · Cited by 1324 — The 2023 guideline is intended to provide patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with aneurysmal subarachnoid",
      "score": 0.10242157
    },
    {
      "number": 15,
      "title": "2023 ACC Expert Consensus Decision Pathway on ...",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jacc.2022.11.022",
      "authors": "www.jacc.org",
      "host": "www.jacc.org",
      "snippet": "Crossref\n\nPubMed\n\nGoogle Scholar\n\n140.\n\n2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for Potentially Inappropriate Medication Use in Older Adults. _J Am Geriatr Soc_. 2019;67:674-694.\n\nCrossref\n\nPubMed\n\nGoogle Sch",
      "score": 0.08182022
    },
    {
      "number": 16,
      "title": "Current Concepts on the Management of Shock | Circulation",
      "detail": "www.ahajournals.org",
      "url": "https://www.ahajournals.org/doi/10.1161/01.CIR.16.6.1097",
      "authors": "www.ahajournals.org",
      "host": "www.ahajournals.org",
      "snippet": "Recent studies have indicated that metaraminol may be the pressor amine of choice because it is therapeutically effective, simple to administer, without risk of",
      "score": 0.036128204
    },
    {
      "number": 17,
      "title": "A prospective evaluation of hemodynamic management in ...",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/sc201332",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "by CY Kong · 2013 · Cited by 59 — We expected that due to neurogenic shock, it would have been more challenging to keep the cervical SCI patients above 80 mm Hg.",
      "score": 0.34362856
    },
    {
      "number": 18,
      "title": "Modeling trajectories of routine blood tests as dynamic biomarkers for outcome in spinal cord injury",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41746-025-01782-0",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "ArticleCASPubMedPubMed CentralGoogle Scholar\n\n7.   Liebscher, T. et al. Cervical spine injuries with acute traumatic spinal cord injury: spinal surgery adverse events and their association with neurological and functional outcome. _Spine_47, E16–E26 (2022).\n\nArticlePubMedGoogle Scholar\n\n8.   Khorasa",
      "score": 0.25401407
    },
    {
      "number": 19,
      "title": "Hyponatremia in spinal cord injury patients: new insight ...",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/sc2014240",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "by J Kriz · 2015 · Cited by 27 — neurogenic shock develops as a result of the loss of autonomic nervous system function below the level of the lesion and needs to be treated",
      "score": 0.1773263
    },
    {
      "number": 20,
      "title": "Spinal cord injury: molecular mechanisms and therapeutic interventions | Signal Transduction and Targeted Therapy",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41392-023-01477-6",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "In terms of prognosis, it has been reported that the mortality of SCI is still high in recent years. SCI mortality rates in developed countries ranged from 3.1 to 22.2%, whereas mortality rates in developing countries ranged from 1.4 to 20.0%.48.\"),384.\"),385.\"),386.\"),387.\"),388.\") Most patients ca",
      "score": 0.14880042
    },
    {
      "number": 21,
      "title": "Spinal Cord Anatomy and Localization | Continuum",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2021/02000/spinal_cord_anatomy_and_localization.4.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Neurogenic shock occurs due to acute pathology above the level of T6, which leads to loss of sympathetic tone below the lesion causing hypotension and",
      "score": 0.26677063
    },
    {
      "number": 22,
      "title": "Key Points for Issue | Continuum",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2024/02000/key_points_for_issue.21.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "This article describes an integrative strategy to evaluate patients with suspected myelopathy, neurogenic shock may manifest with refractory hypotension and",
      "score": 0.2038188
    },
    {
      "number": 23,
      "title": "Spine : Operative Neurosurgery",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/onsonline/fulltext/10.1093/ons/opz073~spine",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "ulcers. Initially after SCI, a state of spine shock with areflexia/hyporeflexia and autonomic dysfunction exists. This state can progress to neurogenic shock, where disconnected sympathetic innervation results in a decreased heart rate, blood pressure, cardiac output, and systemic vascular resistanc",
      "score": 0.18956643
    },
    {
      "number": 24,
      "title": "Urogenital Symptoms in Neurologic Patients",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2017/04000/urogenital_symptoms_in_neurologic_patients.14.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Crossref\n\nGoogle Scholar\n\n21.\n\nde Sèze M, Ruffion A, Denys P, et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. _Mult Scler_ 2007;13(7):915–928. doi:10.1177/1352458506075651.\n\nCrossref\n\nGoogle Scholar\n\n22.\n\nHemmett L, Holmes J, Barne",
      "score": 0.11543139
    }
  ],
  "publishedAt": "2026-08-21T00:28:34.574992+00:00",
  "updatedAt": "2026-08-21T00:28:34.574992+00:00",
  "readingMinutes": 5,
  "slug": "neurogenic-shock"
}